Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Gross Margin (2022 - 2024)

Amylyx Pharmaceuticals has reported Gross Margin over the past 3 years, most recently at 100.0% for Q4 2024.

  • Quarterly results put Gross Margin at 100.0% for Q4 2024, up 1232.0% from a year ago — trailing twelve months through Sep 2025 was 100.0% (up 922.0% YoY), and the annual figure for FY2024 was 93.19%, down 13.0%.
  • Gross Margin for Q4 2024 was 100.0% at Amylyx Pharmaceuticals, roughly flat from 100.0% in the prior quarter.
  • Over the last five years, Gross Margin for AMLX hit a ceiling of 100.0% in Q3 2024 and a floor of 68.56% in Q3 2022.
  • Median Gross Margin over the past 3 years was 93.81% (2023), compared with a mean of 92.0%.
  • Peak annual rise in Gross Margin hit 2636bps in 2023, while the deepest fall reached -170bps in 2023.
  • Amylyx Pharmaceuticals' Gross Margin stood at 89.38% in 2022, then decreased by -2bps to 87.68% in 2023, then rose by 14bps to 100.0% in 2024.
  • The last three reported values for Gross Margin were 100.0% (Q4 2024), 100.0% (Q3 2024), and 99.22% (Q2 2024) per Business Quant data.